INDUSTRY-UNIVERSITY COOPERATION FOUNDATION SOGANG UNIVERSITY
发明人:
KIM, HYUN CHEOL,김현철
申请号：
KR1020110018337
公开号：
KR1020120099862A
申请日:
2011.03.02
申请国别(地区):
KR
年份:
2012
代理人:
摘要：
PURPOSE: A pharmaceutical composition for retinal disorder including a FcRn binding inhibitor is provided to enhance medicinal effects for retinal disorder by improving pharmacodynamic efficiency of the retinal disorder therapeutic agent and to reduce side effects or skipping problems caused by frequent administration.CONSTITUTION: A pharmaceutical composition for retinal disorder includes a FcRn(neonate Fc receptor) binding inhibitor. The retinal disorder therapeutic agent is an anti-body medicine. The retinal disorder therapeutic agent is IgG based anti-body medicine. The retinal disorder therapeutic agent is Avastin. The FcRn binding inhibitor is a peptide which inhibits bondage of the Fc part of IgG with the FcRn. The FcRn binding inhibitor is Fc-III peptide. 0.0001-50 wt% of the FcRn binding inhibitor is included based on the total weight. The pharmaceutical composition for retinal disorder prevention includes the retinal disorder therapeutic agent and the FcRn binding inhibitor. The retinal disorder therapeutic agent and the FcRn binding inhibitor are included at a weight ratio of 1: 0.1-100.COPYRIGHT KIPO 2013[Reference numerals] (AA) Avastin inside vitreous (BB) Concentration (CC) Avastin (DD) Avastin+Fc-111본 발명은 FcRn(신생아 Fc 수용체) 결합 저해제를 포함하는 망막질환 치료제의 약효 증진용 약학적 조성물, 및 망막질환 치료제 및 FcRn의 결합 저해제를 포함하는 망막질환 치료용 약학적 조성물에 관한 것으로서, 본 발명을 통해 망막질환 치료제의 약동학적 효율을 향상시킴으로써 망막질환 치료제의 약효를 증진시킬 수 있고, 잦은 투여로 인한 부작용 또는 복약불이행의 문제를 감소시킬 수 있다.
